MindRank Pharma Honored on the '2025 China Innovative Biopharma FNS101' List at the 7th China Pharma Expo
MindRank
AI Drug Developer
On August 1, 2025, the 2025 Seventh China Pharmaceutical Industry Expo (PharmExpo) grandly opened in Suzhou. Marking a decade of China's innovative drug development, the authoritative list jointly initiated by PharmaCircle and CMC-CHINA Pharmaceutical Industry Expo — "Top 101 of China Pharmaceutical Industry 2025" along with the top 10 core industrial chain lists, as well as the innovation-focused "Top 100 Future New Species Awards 2025 (FNS101)" across six sub-categories, were officially unveiled at PharmExpo.MindRank Ranks on "2025 China Innovative Pharmaceutical Companies FNS101" List.
This award selection was conducted by the FNS expert panel, who proactively identified new leaders with the potential to define the future direction of the industry. Based on rigorous data analysis and multi-dimensional professional evaluation, the final selection highlighted benchmark enterprises and outstanding figures in various fields of China's pharmaceutical industry, establishing authoritative industry benchmarks and guiding the high-quality development direction of the industry.MindRank has been successfully selected for its groundbreaking technological innovation, impressive market performance, forward-looking capital operations, and ambition to reshape the industry landscape., marking that its unique innovative genes and growth momentum are highly anticipated, and it is becoming a core new species leading the leap in value of China's pharmaceutical industry.
Currently,MindRank's first GLP-1RA small molecule oral drug, MDR-001, designed and developed through its self-developed systematic AI platform, has successfully completed Phase IIb clinical research. The study results showed that the treatment group achieved a weight loss of up to 10.3% at 24 weeks, with excellent safety and tolerability.MindRank's new anti-tumor drug MRANK-106 has received clinical approval from the U.S. FDA. In the future, MindRank will continue to accelerate the continuous innovation and iteration of its AI pharmaceutical system, while advancing in-depth research and development of innovative drugs in the fields of metabolism and oncology, for the health and well-being of patients in China and around the world.
About MindRank
MindRank is a clinical-stage AI-driven innovative drug discovery company. The company’s vision is to continuously deliver differentiated and highly clinically valuable drug candidates by promoting the integration of various cutting-edge technologies in artificial intelligence and new drug development, thereby making more diseases treatable and restoring health to more lives.
The company owns a self-developed, internationally leading industrial-grade one-stop AI-driven innovative drug R&D platform, including the knowledge graph-based data mining platform PharmKG™, the protein dynamic simulation and structure prediction platform Molecule Dance™, and the one-stop AI drug design platform Molecule Pro™.
MindRank's AI pharmaceutical solutions were rated as one of the "11 most important AI drug R&D breakthrough achievements globally from 2018 to 2020" by the authoritative European and American institution Deep Pharma Intelligence. In 2023, it was included in Forbes' "Forbes Asia 100 to Watch" list, with only 11 startups from mainland China making the list. In 2024, it was selected for Fortune magazine's IMPACT Companies list as one of "China's most socially impactful startups."
MindRank's Self-Developed One-Stop AI Pharmaceutical Platform
Related Reading:
MindRank's Self-Developed WEE1/YES1 Dual Inhibitor Receives FDA Clinical Approval
MindRank Selected as One of the Top 100 Companies to Watch in the 2023 Forbes Asia-Pacific Region
For more information, please visit the website: www.mindrank.ai
Cooperation: bd@mindrank.ai pr@mindrank.ai
Other: info@mindrank.ai